Literature DB >> 8591843

Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.

E Larrea1, N Garcia, C Qian, M P Civeira, J Prieto.   

Abstract

Tumor necrosis factor alpha (TNF-alpha) is a cytokine with pleiotropic properties that is induced in a variety of pathological situations including viral infections. In this work, we analyzed the expression of TNF-alpha gene in patients with chronic hepatitis C. Serum TNF-alpha levels were found to be elevated in all chronic hepatitis C patients including those cases presenting sustained biochemical remission of the disease after interferon therapy. Untreated patients with chronic hepatitis C showed increased TNF-alpha messenger RNA (mRNA) levels in the liver and mononuclear cells as compared with healthy controls. After completion of treatment with interferon, patients experiencing sustained complete response showed values of TNF-alpha mRNA, both in the liver and in peripheral mononuclear cells, within the normal range, significantly lower than patients who did not respond to interferon and than those with complete response who relapsed after interferon withdrawal. Pretreatment values of TNF-alpha mRNA were lower in long-term responders to interferon than in cases who failed to respond to the treatment. Values of TNF-alpha mRNA in the liver or in mononuclear cells were higher in specimens with positive hepatitis C virus (HCV) RNA than in those samples where the virus was undetectable. Neither the intensity of the liver damage nor the amount of HCV RNA in serum or in cells showed correlation with the levels of TNF-alpha transcripts in peripheral mononuclear cells but it was found that high TNF-alpha values were associated with genotype 1b. In conclusion, there is an enhanced expression of TNF-alpha in HCV infection. High levels of this cytokine may play a role in the resistance to interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8591843      PMCID: PMC7165845          DOI: 10.1002/hep.510230203

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  43 in total

1.  Tumour necrosis factor to treat chronic hepatitis B virus infection.

Authors:  N Sheron; J Y Lau; H M Daniels; J Webster; A L Eddleston; G J Alexander; R Williams
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

2.  Tumour necrosis factor production in fulminant hepatic failure: relation to aetiology and superimposed microbial infection.

Authors:  M de la Mata; A Meager; N Rolando; H M Daniels; K T Nouri-Aria; A K Goka; A L Eddleston; G J Alexander; R Williams
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

3.  Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia.

Authors:  F Herrmann; S G Helfrich; A Lindemann; E Schleiermacher; C Huber; R Mertelsmann
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

4.  Increased plasma tumor necrosis factor in severe alcoholic hepatitis.

Authors:  G L Bird; N Sheron; A K Goka; G J Alexander; R S Williams
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

5.  N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study.

Authors:  O Beloqui; J Prieto; M Suárez; B Gil; C H Qian; N García; M P Civeira
Journal:  J Interferon Res       Date:  1993-08

6.  Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes.

Authors:  S Y Ng; P Gunning; R Eddy; P Ponte; J Leavitt; T Shows; L Kedes
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

7.  Molecular cloning of the complementary DNA for human tumor necrosis factor.

Authors:  A M Wang; A A Creasey; M B Ladner; L S Lin; J Strickler; J N Van Arsdell; R Yamamoto; D F Mark
Journal:  Science       Date:  1985-04-12       Impact factor: 47.728

8.  Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure.

Authors:  Y Muto; K T Nouri-Aria; A Meager; G J Alexander; A L Eddleston; R Williams
Journal:  Lancet       Date:  1988-07-09       Impact factor: 79.321

9.  Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses. Differential induction of interleukin 6 and tumor necrosis factor-alpha.

Authors:  J Gosselin; L Flamand; M D'Addario; J Hiscott; J Menezes
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

10.  Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

Authors:  J Camps; S Crisóstomo; M García-Granero; J I Riezu-Boj; M P Civeira; J Prieto
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

View more
  47 in total

1.  Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.

Authors:  Samir K Gupta; Karen Kolz; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2010-12-16       Impact factor: 2.953

2.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

3.  Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Authors:  M Diago; G Castellano; J García-Samaniego; C Pérez; I Fernández; M Romero; O L Iacono; C García-Monzón
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

4.  Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.

Authors:  M J Walsh; J R Jonsson; M M Richardson; G M Lipka; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

5.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection.

Authors:  B Kallinowski; K Haseroth; G Marinos; C Hanck; W Stremmel; L Theilmann; M V Singer; S Rossol
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

7.  Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.

Authors:  A Kaser; D Novick; M Rubinstein; B Siegmund; B Enrich; R O Koch; W Vogel; S H Kim; C A Dinarello; H Tilg
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

Authors:  Curtis Cooper; Stephan Shafran; Susan Greenbloom; Robert Enns; John Farley; Nir Hilzenrat; Kurt Williams; Magdy Elkashab; Nabil Abadir; Manuela Neuman
Journal:  Can J Gastroenterol Hepatol       Date:  2013-11-08

9.  Clastogenic factors as potential biomarkers of increased superoxide production.

Authors:  Ingrid Emerit
Journal:  Biomark Insights       Date:  2007-12-11

10.  Association of chronic viral hepatitis B with insulin resistance.

Authors:  Jeong Gyu Lee; Sangyeoup Lee; Yun Jin Kim; Byung Mann Cho; Joo Sung Park; Hyung Hoi Kim; Jaehun Cheong; Dong Wook Jeong; Yu Hyun Lee; Young Hye Cho; Mi Jin Bae; Eun Jung Choi
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.